Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
3
×
clinical trials
life sciences
national blog main
3
×
boston
drugs
accelerated approval
acute hepatic porphyria
aldehyde
aldeyra therapeutics
allergan
allergic conjunctivitis
alnylam pharmaceuticals
aminolevulinic acid
bristol-myers squibb
clinical data
dry eye disease
genfit
gilead sciences
givosiran
intercept pharmaceuticals
ldl-c
liver
liver disease
madrigal pharmaceuticals
mark pruzanski
nash
national top stories
new york
new york blog main
new york top stories
nonalcoholic steatohepatitis
obeticholic acid
reproxalab
rna interference
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
What
data
3
×
drug
medicine
new
3
×
aldeyra
alnylam
approved
cleared
closer
disclosed
disease
eye
far
fatty
fda
fighting
filing
horizon
inflammation
intercept
interference
known
liver
market
marketed
multiple
nasdaq
nash
nonalcoholic
ok
pharmaceuticals
phase
positive
puts
results
rna
rnai
second
seek
speedy
Language
Current search:
data
×
new
×
" national blog main "
×
" boston top stories "
×
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug